Blog
Published July 1, 2025
China’s pharmaceutical landscape is not only vast in scale but also rapidly evolving with an emphasis on balancing access with affordability. This year’s NRDL update stands out. The introduction of the value rating system continues to raise the bar for clinical innovation, rewarding innovation that truly addresses unmet needs and demonstrates clear differentiation.
The National Reimbursement Drug List (NRDL) in China is a government-approved roster of medications that are covered by the national health insurance system. Inclusion on this list…
Read Now
Blog
Published June 25, 2025
Field sales serve as the primary bridge between companies and healthcare professionals to build trust, provide valuable information and drive product adoption. Effective call planning is essential, as it allows reps to prioritize their engagements, tailor messaging and maximize their impact.
The introduction of new technologies to streamline or enhance field operations comes with inherent challenges, such as resistance to change, training needs and aligning new systems with existing workflows. Quite simply, the field can become overwhelmed.
To overcome these…
Read Now
Blog
Published June 20, 2025
Reflecting on the first half of 2025 including data from AACR, ASCO and EHA, we see several notable trends continuing to shape the oncology landscape. While development follows momentum observed the last few years, these learnings provide a clearer understanding into the next wave of innovation.
Immunotherapy Moves Earlier in the Journey
One of the most notable themes is the continued momentum of PD-L1 therapies moving into earlier lines of treatment. New data supporting neoadjuvant use in solid tumors suggests…
Read Now
Blog
Published June 13, 2025
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to prepare for it.
What is the JCA?
The JCA is a centralized EU initiative designed to harmonize the clinical assessment component of Health Technology Assessments…
Read Now
Blog
Published June 9, 2025
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of ethics committee processes.
The MFG is a key part of Germany’s National Pharmaceutical Strategy, adopted by the federal cabinet in December 2023. This National…
Read Now
Blog
Published May 15, 2025
Data is the great enabler. It is the backbone of modern Customer Relationship Management (CRM) systems. Data enables businesses to understand their customers better, personalize interactions and make informed decisions. Companies that can harness the power of data have a competitive advantage now, but soon it will become a competitive disadvantage if they are unable to use this data.
“All too often we find that our clients struggle to access and organize their many sources of data into a comprehensive…
Read Now
Blog
Published May 8, 2025
The transformative potential of generative AI (GenAI) within the life sciences industry is highlighted in Everest Group’s report, “AI-deas to Action: Operationalizing Generative AI in Life Sciences.”
Fifteen companies were selected for inclusion across three categories:
Broad-based IT/Business Process Organizations (BPOs)
Clinical Research Organizations (CROs)
Life Sciences Specialists
To be included in the report, providers had to have been profiled in past Everest Group PEAK Matrix® assessments with a Harvey score of above five in Innovation and Investment, as…
Read Now
Blog
Published April 29, 2025
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While campaign rhetoric once suggested bold de-regulation with the potential for an industry-friendly reset, the governing reality has been less coherent and opens multiple fronts for…
Read Now
Blog
Published April 22, 2025
The transition to a new CRM system is more than just a technical migration; it’s a strategic choice that requires careful consideration and a strong point of view on what your organization needs for success.
To navigate the CRM transition necessitated by the Salesforce-Veeva split, it’s crucial to generate buy-in from account and field teams to ensure alignment and CRM utilization during and after the transition.
Interested in learning more about the Salesforce-Veeva split?
Read our first blog here.
Strategies…
Read Now
Blog
Published April 8, 2025
A Massive Change in Customer Relationship Management (CRM) Software
The split between Veeva and Salesforce marks a significant shift in the CRM landscape.
Veeva is removing its CRM from the Salesforce cloud in September 2025 to focus on its “Veeva Vault” cloud solution for CRM. Veeva has communicated that it will maintain the current CRM product until September 2030 but will not be making any updates—and that it will absorb the cost of migration to the new Vault platform for…
Read Now
